Benzinga · Aug 7, 2026
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.
VR
NASDAQ · VRDN
Viridian Therapeutics, Inc.
Healthcare · Biotechnology
$24.50
Down-$0.21 (-0.86%)
Updated Aug 21, 2026, 11:50 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.64B
- P/E ratio
- -7.73
- Dividend yield
- 0.00%
- 52-week range
- $13.18 – $30.42
- Volume
- 1.08M
- Avg. volume
- 1.41M
Price performance
VRDN price history
1M range · 0 trading sessions · Daily adjusted prices
VRDN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest VRDN news
The latest Smart Investors Daily articles mentioning VRDN.
Stock researchCompany · Overview
VRDN research
Overview
Company profile and research snapshot.
Company profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.57
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Jun 30, 2026 | Wedbush | Outperform | — |
| Jun 30, 2026 | Truist Securities | Buy | — |
| Jun 30, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.
Benzinga · Aug 6, 2026
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share
SeekingAlpha · Aug 5, 2026
Amgen: First $10 Billion Quarter, More Growth Ahead
Amgen Inc. Q2 beat lifts FY guidance despite LOE headwinds; see portfolio drivers, pipeline catalysts, and M&A limitsâclick to read the AMGN highlights now.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
